⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 2, 2025Open Access

Supplementary Figure 7 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Kaushik Varadarajan Christian X. Cruz Pico Kurt W. Evans Maria Gabriela Raso Yasmeen Q. Rizvi Xiaofeng Zheng Dhruv Chachad Timothy P. DiPeri Bailiang Wang Stephen M. Scott Ming Zhao Argun Akçakanat Antje M. Wengner Timothy A. Yap Funda Meric‐Bernstam

View Full Paper

Ask AI

Bookmark

Share

Key Points

PARPi resistant models demonstrated notable responses to ATR inhibition in certain tumors, enhancing treatment options.
The study highlights the effectiveness of elimusertib in tumors characterized by DNA damage response pathway alterations.
Analysis of genomic alterations in tumor cells corroborated the positive outcomes of ATR kinase inhibition.
Findings suggest that targeting the DNA damage response may improve outcomes for complex genomic alterations.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis reveals response of PARPi resistant models to ATR inhibition, indicating potential therapeutic pathways.

Abstract

Supplementary Figure 7: PARPi resistant models with response to ATR inhibition.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Varadarajan et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd0289d https://doi.org/10.1158/1535-7163.30028657

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 8 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
2Supplementary Figure 9 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
3Supplementary Figure 10 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
4Supplementary Figure 6 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
5Supplementary Figure 1 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025